Correction: TET2 deficiency promotes MDS-associated leukemogenesis - Summary - MDSpire

Correction: TET2 deficiency promotes MDS-associated leukemogenesis

  • By

  • Feiteng Huang

  • Jie Sun

  • Wei Chen

  • Lei Zhang

  • Xin He

  • Haojie Dong

  • Yuhui Wu

  • Hanying Wang

  • Zheng Li

  • Brian Ball

  • Samer Khaled

  • Guido Marcucci

  • Ling Li

  • November 28, 2023

  • 0 min

Share

Objective:

To correct the acknowledgements section of the original article regarding funding sources.

Key Findings:
  • The original acknowledgements section contained inaccuracies.
  • The corrected acknowledgements include specific grants from the NIH and American Cancer Society.
Interpretation:

Accurate reporting of funding sources is crucial for transparency in research.

Limitations:
  • The correction does not address any scientific findings or conclusions of the original study.
Conclusion:

The article has been corrected to ensure proper acknowledgment of funding sources.

Original Source(s)

Correction: TET2 deficiency promotes MDS-associated leukemogenesis

  • by Feiteng Huang, Jie Sun, Wei Chen, Lei Zhang, Xin He, Haojie Dong, Yuhui Wu, Hanying Wang, Zheng Li, Brian Ball, Samer Khaled, Guido Marcucci, Ling Li

  • November 28, 2023

Related Content

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.

Protocol for a randomized controlled trial investigating the effects of sleep extension on body weight and learning in children (More2Sleep)

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy